cycE/CCNE Cancer Research Results

cycE/CCNE, Cyclin E: Click to Expand ⟱
Source:
Type:
Cyclin E regulates multiple downstream molecules, such as the retinoblastoma susceptibility gene (RB1) and the transcription factor E2F.
Cyclin E (Cyclin E1 and Cyclin E2) is the key regulator of the late G1 → S-phase transition.
Cyclin E is a prognostic marker in breast cancer, its altered expression increased with the increasing stage and grade of the tumor.
Cyclin E is a regulatory protein that plays a critical role in the cell cycle, particularly in the transition from the G1 phase to the S phase. Its expression levels can significantly influence cancer progression and patient prognosis.

Cyclin E expression is frequently elevated in various cancers and is generally associated with poor prognosis. Its role in promoting cell cycle progression makes it a potential biomarker for tumor aggressiveness and patient outcomes.


GC, Gastric Adenocarcinoma: Click to Expand ⟱
Stomach/Gastric Cancer

Scientific Papers found: Click to Expand⟱
5356- AL,    Therapeutic role of allicin in gastrointestinal cancers: mechanisms and safety aspects
- Review, GC, NA
Apoptosis↑, TumCP↓, MAPK↓, PI3K↓, Akt↓, NF-kB↓, AntiCan↑, ChemoSen↑, TumCCA↑, Apoptosis↑, BioAv↑, selectivity↑, TGF-β↓, ROS↑, DNAdam↑, p‑P53↑, P21↑, cycD1/CCND1↓, cycE/CCNE↓, CDK4↓, CDK6↓, MMP↓, NF-kB↑, BAX↑, Bcl-2↓, ER Stress↑, Casp↑, AIF↑, Fas↑, Casp8↑, Cyt‑c↑, cl‑PARP↑, Ca+2↑, *NRF2↑, *chemoP↑, *GutMicro↑, CycB/CCNB1↑, H2S↑, HIF-1↓, RadioS↑,
2655- AL,    Allicin and Digestive System Cancers: From Chemical Structure to Its Therapeutic Opportunities
- Review, GC, NA
TGF-β↓, cycD1/CCND1↓, cycE/CCNE↓, CDK1↓, DNAdam↑, ROS↑, BAX↑, JNK↑, MMP↓, p38↑, MAPK↑, Fas↑, Cyt‑c↑, Casp8↑, PARP↑, Casp3↑, Casp9↑, Ca+2↑, ER Stress↑, P21↑, CDK2↓, CDK6↑, TumCCA↑, CDK4↓,
4793- Lyco,    Lycopene treatment inhibits activation of Jak1/Stat3 and Wnt/β-catenin signaling and attenuates hyperproliferation in gastric epithelial cells
- in-vitro, GC, AGS
antiOx↑, AntiCan↑, ROS↓, JAK1↓, STAT3↓, Wnt↓, β-catenin/ZEB1↓, cMyc↓, cycE/CCNE↓, TumCP↓, Risk↓,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress

antiOx↑, 1,   ROS↓, 1,   ROS↑, 2,  

Mitochondria & Bioenergetics

AIF↑, 1,   MMP↓, 2,  

Core Metabolism/Glycolysis

cMyc↓, 1,   H2S↑, 1,  

Cell Death

Akt↓, 1,   Apoptosis↑, 2,   BAX↑, 2,   Bcl-2↓, 1,   Casp↑, 1,   Casp3↑, 1,   Casp8↑, 2,   Casp9↑, 1,   Cyt‑c↑, 2,   Fas↑, 2,   JNK↑, 1,   MAPK↓, 1,   MAPK↑, 1,   p38↑, 1,  

Protein Folding & ER Stress

ER Stress↑, 2,  

DNA Damage & Repair

DNAdam↑, 2,   p‑P53↑, 1,   PARP↑, 1,   cl‑PARP↑, 1,  

Cell Cycle & Senescence

CDK1↓, 1,   CDK2↓, 1,   CDK4↓, 2,   CycB/CCNB1↑, 1,   cycD1/CCND1↓, 2,   cycE/CCNE↓, 3,   P21↑, 2,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State

PI3K↓, 1,   STAT3↓, 1,   Wnt↓, 1,  

Migration

Ca+2↑, 2,   TGF-β↓, 2,   TumCP↓, 2,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature

HIF-1↓, 1,  

Immune & Inflammatory Signaling

JAK1↓, 1,   NF-kB↓, 1,   NF-kB↑, 1,  

Hormonal & Nuclear Receptors

CDK6↓, 1,   CDK6↑, 1,  

Drug Metabolism & Resistance

BioAv↑, 1,   ChemoSen↑, 1,   RadioS↑, 1,   selectivity↑, 1,  

Functional Outcomes

AntiCan↑, 2,   Risk↓, 1,  
Total Targets: 53

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress

NRF2↑, 1,  

Clinical Biomarkers

GutMicro↑, 1,  

Functional Outcomes

chemoP↑, 1,  
Total Targets: 3

Scientific Paper Hit Count for: cycE/CCNE, Cyclin E
2 Allicin (mainly Garlic)
1 Lycopene
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:28  Cells:%  prod#:%  Target#:378  State#:%  Dir#:1
wNotes=0 sortOrder:rid,rpid

 

Home Page